

6th World Congress on Alternatives & Animal Use in the Life Sciences

DRAFT

August 23, 2007
Hotel East21 Tokyo
Japan

Characterization and current status of the LLNA-DA method: a non-RI modified LLNA based on ATP content

DAICEL CHEMICAL INDUSTRIES, LTD.

Analysis Service Center

Kenji Idehara

1239, Shinzaike, Aboshi-ku, Himeji, Hyogo 671-1283, Japan

Phone: +81-79-274-4096

Fax: +81-79-274-5831

E-mail: kn_idehara@daicel.co.jp

What is LLNA-DA?

«A non-RI modified method»

LLNA : Measure ^{3}H -TdR incorporation
to determine the endpoint of cell proliferation



LLNA-DA : Measure ATP content in the lymph node
to determine the cell number at the end of cell proliferation


ATP: Adenosine triphosphate

Principal energy source for all living organisms.

ATP content is known to correlate with living cell number.

Bioluminescence is measured by luciferin-luciferase assay
to determine the ATP content.

Luciferase



LLNA-DA: LLNA modified by Daicel based on ATP content

Agenda

◆ Characterization of LLNA-DA

Method

Results of 31 well-known chemicals

Performance of LLNA-DA

◆ Inter-laboratory validation studies

Summary of results

Protocol of the LLNA-DA method

Day 1 Day 2 Day 3 Day 7 Day 8



CBA/JNCrlj mice
Female, 8–12 wk



Days 1, 2, and 3, and Day 7

↑ Application of chemicals or vehicle control: 25 µL on the dorsum of both ears

↑ Pretreatment with 1% SLS solution: 1 h before each application

Day 8


(24–30 h after the last application)

Excision of auricular lymph nodes


Measurement of ATP content by luciferin-luciferase assay

Procedure of measurement of ATP content


Excision of lymph nodes



Preparation of cell suspension




Measurement of ATP Relative light units (RLU)



Several measurement kits are easily available.
Measuring the ATP is very easy and rapid.
Measurements should be performed immediately after lymph node excision.

Correlation between of cell number and ATP



Wide dynamic range


Detection range:
1,000~500,000 RLU

SI value: 1 to 20

RLU: relative light units

ATP content (RLU) is linearly related to the cell number

Difference between LLNA & LLNA-DA




LLNA

LLNA-DA

Days 1, 2, and 3, and Day 7
Application
+pretreatment with
1% SLS solution

Day 8
Excision of auricular
lymph nodes
Measurement of ATP
(Index of cell number)



Results of extreme or strong sensitizers



Data presented as mean \pm S.D., * $p < 0.05$, ** $p < 0.01$.

AOO: acetone/olive oil (4:1, v/v)

DNCB: 2,4-dinitrochlorobenzene



Summary of results 31 well-known chemicals

GPMT: guinea pig maximization test
 BA: Büchner assay
 HMT: human maximization test
 HPTA: human patch test allergen

Chemicals	LLNA	GPMT/BA	HMT/HPTA
2,4-Dinitrochlorobenzene	+	+	+
p-Phenylenediamine	+	+	+
Toluene diisocyanate	+		
Glutaraldehyde	+		
K ₂ Cr ₂ O ₇	+	+	+
Phthalic anhydride	+		
Trimellitic anhydride	+		
Formaldehyde	+	+	+
Cinnamic aldehyde	+	+	+
Isoeugenol	+	+	+
CoCl ₂	+	+	+
Eugenol	+	+	+
Resorcinol	+	-	+
Benzocaine	+/-	+	+/-
Abietic acid	+	+	+
Hexyl cinnamic aldehyde	+	+	+
Mercaptobenzothiazol	+	+	+
Citral	+	+	+
Hydroxycitronellal	+	+	+
Imidazolidinyl urea	+	+	+
SLS	+	-	-
NISO ₄	-	+	+
Benzalkonium chloride	-	-	+/-
Propyl paraben	-	-	
Diethylphthalate	-	-	
1-Bromobutane	-	-	
Methyl salicylate	-	-	
Chlorobenzene	-	-	
Lactic acid	-	-	
Hexane	-	-	
Isopropanol	-	-	

Performance of LLNA-DA (vs. LLNA)

		LLNA				
		Positive	Negative			
LLNA-DA	Positive	DNCB p-Phenylenediamine Cinnamaldehyde Isoeugenol Eugenol Abietic acid Imidazolidinyl urea Trimellitic anhydride Phthalic anhydride Glutaraldehyde Formaldehyde Hydroxycitronellal	Benzalkonium chloride			
	Negative	Mercaptobenzothiazol				
Comparison		No. of comparisons	Sensitivity	Specificity	Positive predictivity	
LLNA-DA vs. LLNA		30	95% (19/20)	90% (9/10)	95% (19/20)	
					90% (9/10)	
					93% (26/30)	

Performance of LLNA-DA (vs. GPMT/BA)

		GPMT/BA			
		Positive		Negative	
LLNA-DA	Positive	2,4-Dinitrochlorobenzene <i>p</i> -Phenylenediamine Phthalic anhydride Formaldehyde Cinnamic aldehyde Isoeugenol Eugenol Abietic acid Hydroxycitronellal Imidazolidinyl urea Benzocaine	K ₂ Cr ₂ O ₇ CoCl ₂ HCA Citral	Resorcinol SLS Benzalkonium chloride	
	Negative	Mercaptobenzothiazol NISO ₄		Propylparaben Methyl salicylate Chlorobenzene Lactic acid IPA	
	Comparison	No. of comparisons	Sensitivity	Specificity	Positive predictivity
	LLNA-DA vs. GPMT/BA	25	88% (15/17)	63% (5/8)	83% (15/18)
					Negative predictivity
					71% (5/7)
					Accuracy
					80% (20/25)

GPMT: guinea pig maximization test
BA: Buehler assay

Performance of LLNA-DA (vs. HMT/HPTA)


		HMT/HPTA			
		Positive		Negative	
LLNA-DA	Positive	<i>p</i> -Phenylenediamine Formaldehyde Cinnamic aldehyde Isoeugenol Eugenol Resorcinol Abietic acid Citral Hydroxycitronellal Imidazolidinyl urea Benzalkonium chloride	K ₂ Cr ₂ O ₇ CoCl ₂	SLS	
	Negative	Mercaptobenzothiazol NISO ₄ Propylparaben		Methyl salicylate Hexane	
	Comparison	No. of comparisons	Sensitivity	Specificity	Positive predictivity
	LLNA-DA vs. HMT/HPTA	19	81% (13/16)	67% (2/3)	93% (13/14)
					Negative predictivity
				40% (2/5)	79% (15/19)
					Accuracy

HMT: human maximization test
HPTA: human patch test allergen

Summary of EC3 value

Chemical name	LLNA-DA EC3%	LLNA EC3%
2,4-Dinitrochlorobenzene	0.05	0.03~0.09
p-Phenylenediamine	0.35	0.06~0.2
Toluene diisocyanate	0.05	0.11
Glutaraldehyde	0.10	0.10~0.20
K ₂ Cr ₂ O ₇	0.14	0.14
Trimellitic anhydride	0.20	0.22
Formaldehyde	1.16	0.4~0.7
Cinnamic aldehyde	2.98	1.7~3.1
Isoeugenol	2.46, 2.28, 3.40	1.3~1.8
CoCl ₂	3.27	0.82
Eugenol	4.23, 5.09, 5.59	13
Resorcinol	6.44	6.3
Benzocaine	6.57	+/-
Abletic acid	7.90	11.0~14.7
Hexyl cinnamic aldehyde	11.6	4.0~11.9
Citral	15.6	13
Hydroxycitronellal	13.7	20~23
Imidazolidinyl urea	18.8	23.9

Correlation of EC3 (LLNA vs. LLNA-DA)



EC3 values of LLNA-DA and original LLNA are almost in agreement

Reproducibility of EC3 values based on ATP content

Isoeugenol

Concentration (%)	SI value (ATP) ± S.D.		
	Exp. 1	Exp. 2	Exp. 3
Vehicle (AOO)	1.00 ± 0.54	1.00 ± 0.54	1.00 ± 0.30
0.5	1.50 ± 0.54		1.22 ± 0.13
1	2.28 ± 0.60		2.77 ± 1.01
2.5	2.78 ± 0.17	3.11 ± 1.15	3.01 ± 0.98
5	3.39 ± 0.69	4.39 ± 1.25	
10	5.68 ± 1.19	6.77 ± 0.23	
EC3	3.40%	2.28%	2.46%

Eugenol

Concentration (%)	SI value (ATP) ± S.D.		
	Exp. 1	Exp. 2	Exp. 3
Vehicle (AOO)	1.00 ± 0.17	1.00 ± 0.17	1.00 ± 0.09
5	2.92 ± 1.00	2.80 ± 1.08	3.24 ± 0.70
10	7.35 ± 2.62	4.47 ± 0.98	4.79 ± 0.94
25	10.92 ± 3.63	5.62 ± 3.20	7.07 ± 0.44
EC3	5.09%	5.59%	4.23%

4.97% ± 0.69% CV: 14%

Mini-summary

- ◆ We developed a modified LLNA method with a non-RI endpoint (LLNA-DA)
- ◆ In LLNA-DA, we measure the ATP content as the endpoint.
~Luciferin-luciferase reaction~
- ◆ Simple operation to determine the ATP content
and availability of a wide dynamic range
- ◆ Performance of LLNA-DA is similar to that of original LLNA.
- ◆ EC3 of LLNA-DA is almost equal to that of LLNA.

Inter-laboratory validation study


Objectives: To evaluate the reliability and relevance of LLNA-DA

- ⊕ T. Omori (Kyoto University): Study manager
- H. Kojima (JaCVAM): Chemical selector, Chemical and material distributor
- T. Sozu (Osaka University): Biostatistician
- I. Yoshimura (Tokyo University of Science)

Experimental laboratories

National Institute of Health Sciences	Ishihara Sangyo Kaisha, Ltd.
Taisho Pharmaceutical Co., Ltd.	Pias Corporation
Otsuka Pharmaceutical Co., Ltd.	Drug Safety Testing Center Co., Ltd.
Food and Drug Safety Center	TOAEIYO Ltd.
Sumitomo Chemical Co., Ltd.	Nippon Shinyaku Co., Ltd.
Meiji Seika Kaisha, Ltd.	Hoyu Co., Ltd.
Fuji Film Co., Ltd.	Santen Pharmaceutical Co. Ltd.
Biosafety Research Center, Food, Drugs, and Pesticides	Nakano Seiyaku Co., Ltd.
Chemicals Evaluation and Research Institute	Institute of Environmental Toxicology
Daicel Chemical Industries, Ltd.	

Progression of the validation study



Poster session in WC6

August 24, 2007 Room1-B

P2-2082 First inter-laboratory validation study on LLNA-DA

Y. Ikarashi (National Institute of Health Sciences) and co-workers

P2-2083 Second inter-laboratory validation study on LLNA-DA



Y. Kanazawa (Food and Drug Safety Center) and co-workers

P2-2101 Validation studies on LLNA:

Importance of study management

T. Omiri (Kyoto University) and co-workers

Results of HCA in the validation studies



5%, 10%, and 25% hexylcinnamaldehyde (HCA) /AOO

**All 17 laboratories judged HCA as positive.
Small variances were observed in the SI values
at the same concentration.**

Performance of LLNA-DA in the first-round study

Comparison	n	Sensitivity	Specificity	Positive predictivity	Negative predictivity	Accuracy
LLNA-DA vs. GPMT/BA	11	87.5% (7/8)	100% (3/3)	100% (7/7)	75% (3/4)	90.9% (10/11)
LLNA-DA vs. LLNA	12	87.5% (7/8)	75.0% (3/4)	88% (7/8)	75% (3/4)	83.3% (10/12)
LLNA vs. GPMT/BA	11	87.5% (7/8)	100% (3/3)	100% (7/7)	75% (3/4)	90.9% (10/11)

GPMT: guinea pig maximization test
BA: Buehler assay

The sensitivity, specificity, and accuracy of LLNA-DA vs. GPMT/BA are similar to those of LLNA vs. GPMT/BA.

Conclusion


We have developed LLNA-DA—a non-RI LLNA method—in which ATP content is used as the endpoint.

We tested 31 well-known chemicals and confirmed the performance of LLNA-DA.

Two rounds of inter-laboratory validation studies were conducted at 17 facilities.

The results of these studies are acceptable as a catch-up validation study, at least with regard to the 14 examined chemicals.

Thank you for your attention




Performance of LLNA-DA against LLNA and other assays

Comparison	No. of comparisons	Sensitivity	Specificity	Positive predictivity	Negative predictivity
LLNA-DA vs. LLNA	30	95% (19/20)	90% (9/10)	95% (19/20)	90% (9/10)
LLNA-DA vs. GPMT/BA	25	88% (15/17)	63% (5/8)	83% (15/18)	71% (5/7)
LLNA-DA vs. HMT/HPTA	19	81% (15/17)	67% (9/10)	93% (19/20)	40% (9/10)
*LLNA-DA vs. GPMT/BA	97	91% (62/68)	83% (24/29)	93% (62/67)	80% (24/30)
*LLNA-DA vs. HMT/HPTA	74	72% (49/68)	67% (4/6)	96% (49/51)	17% (4/23)

Reference information


Correlation of ATP concentration with relative light unit (RLU)



Correlation of ATP concentration with relative light unit (RLU)


Reference information

Effect of fourth application on Day 7 —Variation in lymph node weight—



Reference information

Effect of pretreatment with 1% SLS solution




Data presented as mean \pm S.D.

* $p < 0.05$, ** $p < 0.01$.

Reference information

Variation in EC3 by difference of endpoints for isoeugenol





EC3 = 8.02% (LN weight)


EC3 = 2.28% (ATP)

EC3 = 0.31% (Cell number)


EC3 = 1.3~3.3%

(Original LLNA)




Reference information**Results of weak sensitizers**

Data presented as mean \pm S.D., * $p < 0.05$, ** $p < 0.01$.
AOO: acetone/olive oil (4:1, v/v)

Reference information**Results of metal salts**


Data presented as mean \pm S.D., * $p < 0.05$, ** $p < 0.01$.
DMSO: dimethylsulfoxide

Reference information**Using DMF as vehicle**

Data presented as mean \pm S.D., * $p < 0.05$, ** $p < 0.01$.

DMF ; N, N-Dimethylformamide

MBT ; 2-Mercaptobenzothiazole

Reference information**False positive substances**

Data presented as mean \pm S.D., * $p < 0.05$, ** $p < 0.01$.

DMF ; N, N-Dimethylformamide

AOO: acetone/olive oil (4:1, v/v)

SLS: Sodium lauryl sulfate

■ The red bar ;

$$SI = \frac{\text{mean ATP content (RLU)} \\ \text{of chemical treatment group}}{\text{mean ATP content (RLU)} \\ \text{of vehicle treatment group}}$$

Cut-off point ;
positive, $SI \geq 3$ and negative, $SI < 3$